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Idiopathic Hyperammonemia and Rituximab Therapy
Samer Bolis DO, Daniel E. Schwed, MD and James M. Ross, MD
Lehigh Valley Health Network, Allentown, Pennsylvania
INTRODUCTION

DISCUSSION

Hyperammonemia is most commonly encountered as a complication of hepatic dysfunction. As ammonia
levels acutely rise, neurons suffer oxidative and mechanical stress due to increased intracellular osmolarity.
There is no numeric cutoff to predict clinical impairment, but high enough concentrations can lead to coma
and even death. Recognition and management of non-hepatic hyperammonemia in adult patients is a great
challenge as such cases are not often encountered, tend to be persistent, with rapid progression to a poor
prognosis.

Several medications i.e., Valproic acid, are known for their
potential to disrupt the hepatic urea cycle, causing mild
elevations in serum ammonia. Several reports have observed
hyperammonemia with levels comparable to our patient’s
following high-dose chemotherapy. While Rituximab is
implicated in multiple cases, it has never been documented
as being the sole culprit in patients with hyperammonemic
encephalopathy. Given its prolonged half-life, we suspect
that Rituximab contributed to our patient’s hyperammonemia,
making this case iatrogenic in nature. The fact that the patient
was not encephalopathic until serum ammonia reached levels
>800, suggests that this was a chronic process rather than an
acute hyperammonemia. In this case, when a CD 19 count was
checked, it was found to be <1, indicating that Rituximab was
still active. Proposed mechanisms suggest that Rituxumab may
unmask mild or compensated urea cycle deficits. For instance,
orthinthine transcarbamylase deficiency is X-linked and only 10
percent of female carriers become symptomatic, sometimes late
in life. Despite the non-specific findings on serum amino acid
analysis, enzymatic deficiencies of hepatic urea cycle cannot
be ruled out. The diagnosis of inborn errors of metabolism is
difficult to make in the setting of an acute illness and often
cannot be confirmed for days or sometimes months after the
initial presentation.

CASE PRESENTATION
A 69 year-old female with no known history of inborn errors of metabolism or hepatic dysfunction
presented with acute encephalopathy and was noted to be hyperammonemic (Serum ammonia of 860).
She was treated with Rituximab (a monoclonal antibody against CD20) approximately 6 weeks prior for
a cryoglobulinemic vasculitis and polyarticular inflammatory arthritis. She was initially managed with
lactulose and rifaxamin, demonstrating improvement in mental status with decreased yet fluctuating
ammonia levels (Approximately 150). Work up yielded no obvious explanation for the high ammonia levels.
There were no signs of gastrointestinal
hemorrhage, infection with urease-producing
bacteria, seizures, intoxication of any sort,
or hepatic dysfunction. By day 10 of her
hospitalization, her serum ammonia gradually
increased to levels >1000 with rapidly
worsening and recurrent encephalopathy.
Hyperammonemia reached a level as high as
1370 and was refractory to renal replacement
therapy. The patient increasingly became
hemodynamically unstable with eventual
expiration within 48 hrs. Further investigation
of serum amino acid levels suggested no
enzymatic deficiencies to diagnose urea cycle
disorders. An autopsy was declined by family
members.
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